Reinsurance Group of America (NYSE:RGA – Get Free Report) had its target price dropped by Evercore ISI from $280.00 to ...
2d
Stocktwits on MSNCapital One Stock Gets An Evercore ISI Upgrade To ‘Outperform’ — But Retail’s On The FenceCapital One Financial Corp (COF) shares attracted investor attention Wednesday morning after Evercore ISI upgraded the stock ...
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Hold rating on Caribou Biosciences (CRBU – Research Report), with a ...
Evercore ISI upgraded Capital One Financial to Outperform from In Line, bolstered by the conviction that the bank's ...
Evercore ISI initiated coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The firm issued an ...
Evercore ISI analyst Amit Daryanani maintained a Buy rating on Vertiv Holdings (VRT – Research Report) yesterday and set a price target of ...
2d
Fintel on MSNEvercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform RecommendationFintel reports that on March 12, 2025, Evercore ISI Group initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...
Evercore ISI upgraded Capital One Financial Corp (NYSE:COF) to "Outperform" from "In Line," focusing on long-term earnings upside from its pending acquisition of Discover Financial Services (NYSE:DFS) ...
Evercore ISI analysts warned in a note Monday that stagflation fears are mounting, with tariff policies and economic uncertainty creating potential downside risks for the S&P 500.
Evercore ISI analyst Chris McNally has lowered EV giant Tesla’s price target from $270 to $235, citing ongoing market concerns and company-specific challenges. The price downgra ...
Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $80.00. The company’s shares clos ...
Fintel reports that on March 12, 2025, Evercore ISI Group initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Outperform recommendation. As of March 4, 2025, the average one-year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results